{"SPADE_N_14447": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14447", "Peptide Name": "PSTO2 SR (Phylloseptin-TO2 analog, synthetic AMPs, XXA, UCLL1c)", "Source": "amino acid substitution, amphibian peptide analog, animal-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "FLSLIPKAIKAVSALAKKL", "Sequence Length": 19, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Antifungal", "Antifungal", "Anti-MRSA", "anti-sepsis", "Hemolytic", "Antibiofilm", "Anticancer"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2011.54, "PI": 10.48, "Hydrophobicity": 1.03, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Yin W, Yao J, Leng X, Ma C, Chen X, Jiang Y, Wang T, Chen T, Shaw C, Zhou M, et al. 2024", "Reference": "Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098.MDPI", "Title": "Enhancement of Antimicrobial Function by L/D-Lysine Substitution on a Novel Broad-Spectrum Antimicrobial Peptide, Phylloseptin-TO2: A Structure-Related Activity Research Study"}], "Frequent Amino Acids": "AKL", "Absent Amino Acids": "CDEGHMNOQRTUWY", "Basic Residues": 4, "Acidic Residues": 0, "Hydrophobic Residues": 13, "Polar Residues": 11, "Positive Residues": 4, "Negative Residues": 0, "Net Charge": 4, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (94.74%) toPSTO2 18KL=A=K: 21%, S: 11%; I: 11%.Activity: active against Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493 (MIC 2 uM), Gram- E. coli ATCC 8739 (MIC 2 uM), A. baumannii BAA 747 (MIC 4 uM),  K. pneumonia ATCC 43816 (MIC 2 uM), P. aeruginosa ATCC 9027 (MIC 16 uM), and fungi C. albicans (MIC 32 uM). Rapid killing at 2xMIC. It binds to LPS.  inhibit biofilms:bacteria (S. aureus and E. coli); eradicate preformed biofilms:S. aureus.Antimicrobial robustness: NaCl-insensitive:S. aureus; KCl-insensitive:S. aureus; NH4Cl-insensitive:S. aureus;  CaCl2-insensitive:S. aureus; MgCl2-insensitive:S. aureus; FeCl3-insensitive:S. aureus. NaCl-sensitive:E. coli; KCl-insensitive:E. coli; NH4Cl-insensitive:E. coli;  CaCl2-sensitive:E. coli; MgCl2-insensitive:E. coli; FeCl3-insensitive:E. coli. serum-insensitive:S. aureus (10% FBS);  serum-sensitive:E. coli (10% FBS).MOA:bacteria:  it permeated bacterial membranes of S. aureus MRSA. Also permeated the outer membranes of E. coli.Structure: random coils in 10 mM NH4Ac and helical in 50% TFE.In vitro toxicity: horse RBC: HC50 64 uM. It showed toxicity to both cancer and non-cancer cells.", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_26441", "Similarity": 1.0, "Sequence": "FLSLIPKAIKAVSALAKKL"}, {"SPADE_ID": "SPADE_UN_26443", "Similarity": 1.0, "Sequence": "FLSLIPKAIKAVSALAKKL"}, {"SPADE_ID": "SPADE_UN_17620", "Similarity": 1.0, "Sequence": "LAKKLKEYLEKLV"}]}}}